CD4+ T-Reg cell therapy (Bit Bio/BlueRock)

N/A

Report date: 2024/09/03 10:06:43

Base Information

Drug NameCD4+ T-Reg cell therapy (Bit Bio/BlueRock)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsUpdating
Therapy Area/IndicationsAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBluerock Therapeutics LpBit Bio Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBluerock Therapeutics LpBit Bio Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A